1,726,444 research outputs found
Resumen ejecutivo de los documentos ALADI/SEC/di 3022 y 3023
No full textSecretaría General de la ALADI.Informe mensual sobre el comportamiento del gasto presupuestal para el período enero-marzo 2022 (ALADI/SEC/di 3022) -- Informe sobre la situación financiera de la Asociación al 31 de marzo de 2022 (ALADI/SEC/di 3023)
NS 3022 Ultra, hibrid kukuruza
No full textOvo je novostvoreni hibrid kukuruza (Zea mays L.) NS 3022 Ultra priznat od strane Uprave za zaštitu bilja Ministarstva poljoprivrede, šumarstva i vodoprivrede Republike Srbije.This is registered newly-developed hybrid of maize (Zea mays L.) NS 3022 Ultra released by the Plant Protection Directorate of the Ministry of Agriculture, Forestry and Water Management of the Republic of Serbia.Broj rešenja: 320-04-02449/2/2019-11
Datum rešenja: 11.03.2021
Financial Accounting 111: FAC 3022
No full textExamination on Financial Accounting 111: FAC 3022, Oct/Nov 201
Astronomische nachrichten, nos 3019-3022
No full textR. R. Astronomische nachrichten, nos 3019-3022. In: Bulletin astronomique, tome 8, 1891. pp. 179-184
Financial Management III (MOD 2): FIM 3022
No full textExamination on Financial Management III (MOD2): FIM 3022, Nov 201
Financial Information Systems I : FIM 3022
No full textExamination on Financial Information Systems I : FIM 3022, November 201
Financial Information Systems III : FIS 3022
No full textExamination on Financial Information Systems III : FIS 3022, 2013 Examinatio
Effect of KBT-3022, a New Diphenylthiazole Derivative, on Platelet Functions
No full textAbstract
The effects of KBT-3022 and its metabolite desethyl KBT-3022 on platelet aggregation were determined in rat, guinea-pig, rabbit and human platelets in-vitro and ex-vivo.
KBT-3022 and desethyl KBT-3022 inhibited platelet aggregation induced by arachidonic acid and collagen in-vitro more potently than aggregation induced by adenosine diphosphate, platelet-activating factor or thrombin, as well as by acetylsalicylic acid, and their effects were approximately 100 times more potent than those of acetylsalicylic acid.
Desethyl KBT-3022, but not KBT-3022 or acetylsalicylic acid, inhibited thrombin-induced aggregation and 5-hydroxytryptamine release from platelets more potently than ticlopidine hydrochloride at higher concentrations. Oral administration of KBT-3022 inhibited both arachidonic acid- and collagen-induced platelet aggregation and reduced platelet retention in a glass-bead column approx. 100 times more potently than acetylsalicylic acid. KBT-3022 showed little or no anti-inflammatory effect on either ultraviolet-induced erythema or arachidonic acid induced ear oedema, and had lower gastro-ulcerogenicity than acetylsalicylic acid.
These results suggest that KBT-3022 is a potent inhibitor of platelet activation with weak side-effects.</jats:p
- …
